Eric T Wong

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Taming glioblastoma: targeting angiogenesis
    Eric T Wong
    J Clin Oncol 25:4705-6. 2007
  2. ncbi request reprint Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 6:515-22. 2008
  3. pmc Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts, 02215, USA
    BMC Cancer 16:914. 2016
  4. pmc An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA
    Curr Treat Options Oncol 16:40. 2015
  5. pmc Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma
    Eric T Wong
    Department of Neurology
    Biologics 1:321-4. 2007
  6. pmc Polyradiculopathies from schwannomatosis
    Yuxia Jia
    Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center
    Open Neuroimag J 5:9-13. 2011
  7. pmc The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo
    Renquan Lu
    Department of Biochemistry and Molecular Biology and the Key Laboratory of Molecular Medicine, Ministry of Education, Shanghai 200032, China
    BMC Cancer 12:607. 2012
  8. pmc Superior semicircular canal dehiscence in East Asian women with osteoporosis
    Alexander Yu
    South Cove Community Health Center, Boston, MA, USA
    BMC Ear Nose Throat Disord 12:8. 2012
  9. ncbi request reprint Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Natl Compr Canc Netw 9:403-7. 2011
  10. pmc Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
    Eric T Wong
    Beth Israel Deaconess Medical Center, Brain Tumor Center and Neuro Oncology Unit, Boston, MA 02215, USA
    Cerebrospinal Fluid Res 5:1. 2008

Detail Information

Publications47

  1. ncbi request reprint Taming glioblastoma: targeting angiogenesis
    Eric T Wong
    J Clin Oncol 25:4705-6. 2007
  2. ncbi request reprint Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 6:515-22. 2008
    ....
  3. pmc Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts, 02215, USA
    BMC Cancer 16:914. 2016
    ..The treatment goal for recurrent malignant gliomas centers on disease stabilization while minimizing therapy-related side effects. Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective...
  4. pmc An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA
    Curr Treat Options Oncol 16:40. 2015
    ..Therefore, it is likely that the efficacy of TTFields can be increased by combining it with other anti-cancer treatment modalities...
  5. pmc Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma
    Eric T Wong
    Department of Neurology
    Biologics 1:321-4. 2007
    ..More importantly, timely recognition of this disease and the use of large fraction radiation therapy are necessary to control rapid neurologic deterioration...
  6. pmc Polyradiculopathies from schwannomatosis
    Yuxia Jia
    Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center
    Open Neuroimag J 5:9-13. 2011
    ..This case highlights the importance of using MRI and INI1 immunohistochemistry to differentiate familial schwannomatosis, neurofibromatosis 2 (NF2)-associated schwannomatosis, and sporadic schwannomatosis...
  7. pmc The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo
    Renquan Lu
    Department of Biochemistry and Molecular Biology and the Key Laboratory of Molecular Medicine, Ministry of Education, Shanghai 200032, China
    BMC Cancer 12:607. 2012
    ..The mechanisms for the highly invasive behavior of gliomas are still poorly understood. The aim of this study was to examine whether brevican is a predictor of glioma and its roles in glioma cell motility...
  8. pmc Superior semicircular canal dehiscence in East Asian women with osteoporosis
    Alexander Yu
    South Cove Community Health Center, Boston, MA, USA
    BMC Ear Nose Throat Disord 12:8. 2012
    ..We document a case series of elderly East Asian women with atypical SSCD symptoms, radiologically confirmed dehiscence and concurrent osteoporosis...
  9. ncbi request reprint Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Natl Compr Canc Netw 9:403-7. 2011
    ..The efficacy benchmarks from this meta-analysis did not differ from those of the recently published randomized phase II studies. The lack of a dose--response effect would require confirmation in a prospectively conducted clinical trial...
  10. pmc Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
    Eric T Wong
    Beth Israel Deaconess Medical Center, Brain Tumor Center and Neuro Oncology Unit, Boston, MA 02215, USA
    Cerebrospinal Fluid Res 5:1. 2008
    ..This study determined whether doxycycline can block MMP activity in vitro. We also measured MMP-2 and MMP-9 levels in cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas...
  11. ncbi request reprint Matrix metalloprotease-9 in cerebrospinal fluid correlates with disease activity in lymphomatous meningitis
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Lymphoma Myeloma 7:305-8. 2007
    ..We hypothesize that matrix metalloproteases (MMPs) would be important in lymphomatous meningitis because lymphoma cells may produce MMPs for brain invasion and angiogenesis...
  12. ncbi request reprint Cyberknife radiosurgery for basal skull plasmacytoma
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Neuroimaging 16:361-3. 2006
    ..To our knowledge, this is a first case of successful Cyberknife radiosurgery of a medullary plasmacytoma...
  13. ncbi request reprint Tumor growth, invasion, and angiogenesis in malignant gliomas
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Department of Neurology, Harvard Medical School, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Neurooncol 77:295-6. 2006
  14. ncbi request reprint Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities
    Eric T Wong
    Department of Neurology and Neuro Oncology Unit, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 11:7151s-7157s. 2005
    ..Our review summarizes the biological behaviors of CNS lymphomas and the challenges and opportunities in using mAbs for CNS lymphomas...
  15. ncbi request reprint Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm
    Eric T Wong
    Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Expert Opin Pharmacother 6:1107-14. 2005
    ..This article will review the biology of CNS lymphomas, monoclonal antibody technology, limitation of existing chemotherapies and the application of therapeutic monoclonal antibodies for the treatment of CNS lymphomas...
  16. ncbi request reprint Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Harvard Medical School Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Cancer 101:139-45. 2004
    ..The authors report their experience with an immunochemotherapy regimen consisting of rituximab and temozolomide in patients with primary or metastatic CNS lymphoma...
  17. ncbi request reprint The role of topotecan in the treatment of brain metastases
    Eric T Wong
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Oncologist 9:68-79. 2004
    ..This review summarizes the available preclinical and clinical evidence for the role of topotecan in the treatment of brain metastases and concludes with three case studies...
  18. doi request reprint Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 78:85-90. 2010
    ..We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ)...
  19. pmc A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy
    Eudocia Q Lee
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts E Q L, D A R, A D N, L N, M L R, B M A, N D A, L D, J S, D L, S F R, J P, K H S, S C G, S H, P Y W Harvard Medical School, Boston, Massachusetts E Q L, E T W, D A R, A D N, L N, M L R, B M A, N D A, P Y W Massachusetts General Hospital, Boston, Massachusetts A M University of Pittsburgh, Pittsburgh, Pennsylvania J D University of California San Diego, La Jolla, California S K Beth Israel Deaconess Medical Center, Boston
    Neuro Oncol 18:849-54. 2016
    ..Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT...
  20. doi request reprint Phase I study of GRN1005 in recurrent malignant glioma
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 19:1567-76. 2013
    ..We conducted a first-in-human phase I trial of GRN1005 in patients with recurrent glioma...
  21. doi request reprint Melanoma brain metastasis: overview of current management and emerging targeted therapies
    Ekokobe Fonkem
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Expert Rev Neurother 12:1207-15. 2012
    ..Additional clinical trials of newer agents involving these pathways are also showing promise. Therefore, targeted therapies must be incorporated into the multimodality management of melanoma brain metastasis...
  22. doi request reprint The natural history of extracranial metastasis from glioblastoma multiforme
    Melody Lun
    Department of Neurology, Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Neurooncol 105:261-73. 2011
    ..We conclude that patients with glioblastoma extracranial metastasis have poor prognosis, but there has been a progressive lengthening of survival in each successive decade from 1940 to 2000...
  23. pmc Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy
    Anand Mahadevan
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA
    Radiat Oncol 10:245. 2015
    ..In this study, we found that multi-field intensity modulated radiation therapy (IMRT), with strict constraints to the brain parenchyma and to the hippocampus, reduces follicular scalp dose and prevents alopecia...
  24. pmc Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
    Deepa Rangachari
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
    Lung Cancer 88:108-11. 2015
    ..In this study, we evaluated the frequency of BM in patients with epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged NSCLC...
  25. doi request reprint Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy
    Xing Qi Lu
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 71:281-9. 2008
    ..However, the effect of deformation, defined as any changes in the body and organs relative to the center of fiducials, remains unanswered. This study investigated this problem and a possible solution...
  26. ncbi request reprint NovoTTF-100A: a new treatment modality for recurrent glioblastoma
    Ekokobe Fonkem
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Expert Rev Neurother 12:895-9. 2012
    ..NovoTTF-100A is a new modality of cancer treatment that offers equivalent efficacy, but less toxicity, to recurrent glioblastoma patients when compared with existing treatments...
  27. pmc Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial
    Scott R Floyd
    Beth Israel Deaconess Medical Center Boston, MA, USA Harvard Medical School Boston, MA, USA
    Front Oncol 2:122. 2012
    ..There was no additional toxicity. These results indicate that elderly patients with good KPS can achieve outcomes comparable to the current standard of care using an abbreviated radiotherapy course, radiosurgery boost, and temozolomide...
  28. pmc RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN
    Seongmi Park
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8813, USA
    Cancer Res 69:4107-11. 2009
    ..Our data suggest that the RIP1-NF-kappaB status of tumors may influence response to treatments targeting the PTEN-PI3K-mTOR signaling axis...
  29. pmc A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
    Eudocia Q Lee
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 21:3610-8. 2015
    ..We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide with or without vandetanib in patients with newly diagnosed glioblastoma (GBM)...
  30. pmc Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma
    Jason W Locasale
    Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston Massachusetts 02115, USA
    Mol Cell Proteomics 11:M111.014688. 2012
    ....
  31. pmc The natural history of intravascular lymphomatosis
    Ekokobe Fonkem
    Brain Tumor Center and Neuro Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Cancer Med 3:1010-24. 2014
    ..Timely diagnosis and treatment with rituximab-based chemotherapy improve patient survival. The pattern of recurrence is different between CNS IVL and IVL's in other organs...
  32. pmc Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Cancer Med 3:592-602. 2014
    ..2900). Our results indicate that the response characteristics favor NovoTTF-100A and data on prior low-grade histology and dexamethasone suggest potential genetic and epigenetic determinants of NovoTTF-100A response...
  33. pmc The cerebrospinal fluid provides a proliferative niche for neural progenitor cells
    Maria K Lehtinen
    Division of Genetics, Howard Hughes Medical Institute, Children s Hospital Boston, Boston, MA 02115, USA
    Neuron 69:893-905. 2011
    ..The temporal control of CSF composition may have critical relevance to normal development and neuropathological conditions...
  34. doi request reprint A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme
    Jan Drappatz
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 73:222-7. 2009
    ....
  35. pmc An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma
    Kenneth D Swanson
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Curr Neurol Neurosci Rep 16:8. 2016
    ..These observations have a profound impact on the use of TTFields in the clinic, including what co-therapies may be best applied to boost its efficacy. ..
  36. doi request reprint Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations
    Edwin Lok
    a 1 Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Expert Rev Med Devices 12:717-26. 2015
    ..Here, we summarize our current knowledge of the physics, cell biology and clinical data supporting the use of the tumor treating fields therapy. ..
  37. pmc Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid
    Edwin Lok
    Brain Tumor Center and Neuro Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Melanoma Res 24:120-30. 2014
    ..These alterations likely drive the course of this disease in the brain and variations in the immune profiles of individual patients may predict outcomes. ..
  38. pmc Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation
    Eric T Wong
    Brain Tumor Center and Neuro Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    Cancer Med 4:383-91. 2015
    ....
  39. ncbi request reprint Illusion of stroke: intravascular lymphomatosis
    Soma Sengupta
    Department of Neurology, Harvard Medical School, Boston, MA, USA
    Rev Neurol Dis 8:e107-13. 2011
    ..Intravascular lymphomatosis can be treated with systemic chemotherapies, but the response rate and pattern of relapse remain unknown...
  40. pmc Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3 Tesla
    Rachel Scheidegger
    Harvard MIT Division of Health Sciences and Technology, 77 Massachusetts Ave E25, Cambridge, MA 02139, USA Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA Electronic address
    Neuroimage 99:256-68. 2014
    ..Robust acquisition strategies that effectively isolate the contributions of broad macromolecular MTC asymmetry from amine exchange were demonstrated that may provide improved contrast between glioma and normal tissue. ..
  41. pmc Computed modeling of alternating electric fields therapy for recurrent glioblastoma
    Edwin Lok
    Brain Tumor Center and Neuro Oncology Unit, Department of Neurology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Cancer Med 4:1697-9. 2015
    ..Future improvement in TTFields treatment may need to take into account the inhomogeneity of the electric field distribution within the brain...
  42. pmc Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit
    Nidhi Gera
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 10:e0125269. 2015
    ..Thus, TTFields are able to diminish cell proliferation by specifically perturbing key proteins involved in cell division, leading to mitotic catastrophe and subsequent cell death. ..
  43. doi request reprint Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy
    Lawrence Recht
    Department of Neurology, Advanced Medicine Clinic, Stanford University School of Medicine, 875 Blake Wilbur Dr, Stanford, CA 94305, USA
    J Clin Oncol 31:1182-7. 2013
    ..To compare the safety and efficacy of corticorelin acetate (CrA) and placebo in patients with malignant brain tumors requiring chronic administration of dexamethasone (DEX) to control the signs and symptoms of peritumoral brain edema (PBE)...
  44. ncbi request reprint Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells
    Deepti B Ramnarain
    Department of Neurology, University of Texas Southwestern Medical Center, 6001 Forest Park ND4 136, Dallas, TX 75390, USA
    Cancer Res 66:867-74. 2006
    ..Thus, our study provides a new insight into oncogenic signaling by EGFRvIII and improves our understanding of how autocrine loops are generated in glioma...
  45. doi request reprint Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
    Patrick Y Wen
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:1963-72. 2010
    ..In this proposal, we present the recommendations for updated response criteria for high-grade gliomas...
  46. ncbi request reprint Is protracted low-dose temozolomide feasible in glioma patients?
    Eric T Wong
    Neurology 67:543-4; author reply 543-4. 2006
  47. ncbi request reprint Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
    Eric T Wong
    Neurology 64:934; author reply 934. 2005